Sanofi, Regeneron phase 3 trial of Libtayo in advanced cervical cancer stopped early for positive result Ruchika Sharma17 March 2021 10:00 AM ISTParis and Tarrytown: Positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating Sanofi and Regeneron's PD-1...
Sanofi, Regeneron win EU patent case against Amgen over Praluent Ruchika Sharma1 Nov 2020 11:15 AM IST"We are pleased with today's decision by the European Patent Office, which upholds the rigorous standard for pharmaceutical patents that we argued for...
Setback: Eli Lilly antibody drug fails in a Covid19 study, others go on Ruchika Sharma27 Oct 2020 2:20 PM ISTAnnapolis: US government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalised with Covid-19...
Sanofi, Regeneron arthritis drug Kevzara fails COVID-19 study Ruchika Sharma4 July 2020 10:00 AM ISTParis: Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the U.S. Phase 3 trial of Kevzara (sarilumab) 400 mg in COVID-19 patients...
Sanofi to present growth opportunities, development strategy for Dupixent in type 2 inflammatory diseases Ruchika Sharma14 Jun 2020 9:15 AM ISTAs announced in December 2019, Sanofi expects to deliver strong growth for Dupixent with the ambition of achieving more than €10 billion in peak sales...
Sanofi plans to sell its equity investment in Regeneron; confirms no change to ongoing collaboration Hina Zahid27 May 2020 2:17 PM ISTParis: Sanofi has announced its intent to sell its equity investment in Regeneron through a registered public offering and related share repurchase by...
